Cite
HARVARD Citation
de Latour, R. et al. (2022). Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet. 9 (9), pp. e648-e659. [Online].